Ruth Henquin
Research Subjects
Ruth Henquin has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alfonsina Candiello
Instituto Cardiovascular de Buenos Aires
3 shared publications - Fernando A. Cura
Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
3 shared publications - Fernando Botto
Department of Cardiology and Research Unit, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina
3 shared publications - Fernando Piccinini
Servicio de Cirugía cardiovascular, Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina
3 shared publications Marcelo Trivi
3 shared publicationsMaría F. Castro
3 shared publications
Latest Publications
- Open Access
- 25 August 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Impacto de un Heart Team en pacientes con estenosis aórtica candidatos a reemplazo percutáneo.
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not. How to cite this article: Trivi MS, Castro MF, Trossero R, Cura FA, Piccinini FF, Candiello F, y cols. Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement. Rev Argent Cardiol 2023;91:246-51. http://dx.doi.org/10.7775/rac.v91.i4.20649
- 25 August 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Open AccessImpacto de un Heart Team en pacientes con estenosis aórtica candidatos a reemplazo percutáneo.
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not. How to cite this article: Trivi MS, Castro MF, Trossero R, Cura FA, Piccinini FF, Candiello F, y cols. Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement. Rev Argent Cardiol 2023;91:246-51. http://dx.doi.org/10.7775/rac.v91.i4.20649
- Open Access
- 25 August 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Impacto de un Heart Team en pacientes con estenosis aórtica candidatos a reemplazo percutáneo.
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not. How to cite this article: Trivi MS, Castro MF, Trossero R, Cura FA, Piccinini FF, Candiello F, y cols. Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement. Rev Argent Cardiol 2023;91:246-51. http://dx.doi.org/10.7775/rac.v91.i4.20649
- 25 August 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Open AccessImpacto de un Heart Team en pacientes con estenosis aórtica candidatos a reemplazo percutáneo.
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not. How to cite this article: Trivi MS, Castro MF, Trossero R, Cura FA, Piccinini FF, Candiello F, y cols. Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement. Rev Argent Cardiol 2023;91:246-51. http://dx.doi.org/10.7775/rac.v91.i4.20649
- 1 August 2023
- Published by Revista Argentina de Cardiologia
- Vol. 91 (4) , 246-251
Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not.
- 1 August 2023
- Published by Revista Argentina de Cardiologia
- Vol. 91 (4) , 246-251
Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not.